- Home
- STAA
as of 03-26-2026 3:46pm EST
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | MONROVIA |
| Market Cap: | 867.9M | IPO Year: | 1995 |
| Target Price: | $22.19 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Hold | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | -295.12 |
| 52 Week Low/High: | $14.69 - $30.81 | Next Earning Date: | 03-03-2026 |
| Revenue: | $239,442,000 | Revenue Growth: | -23.72% |
| Revenue Growth (this year): | 27.04% | Revenue Growth (next year): | 7.27% |
| P/E Ratio: | -11.85 | Index: | N/A |
| Free Cash Flow: | -40050000.0 | FCF Growth: | N/A |
AI-Powered STAA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of STAAR Surgical Company (STAA)
10% Owner
Avg Cost/Share
$11.03
Shares
27,485
Total Value
$606,137.70
Owned After
15,453,629
10% Owner
Avg Cost/Share
$10.97
Shares
3,240
Total Value
$71,082.04
Owned After
15,453,629
10% Owner
Avg Cost/Share
$11.00
Shares
66,467
Total Value
$1,462,300.59
Owned After
15,453,629
10% Owner
Avg Cost/Share
$10.85
Shares
336,946
Total Value
$7,284,281.10
Owned After
15,453,629
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| BROADWOOD PARTNERS, L.P. | STAA | 10% Owner | Jan 9, 2026 | Buy | $11.03 | 27,485 | $606,137.70 | 15,453,629 | |
| BROADWOOD PARTNERS, L.P. | STAA | 10% Owner | Jan 8, 2026 | Buy | $10.97 | 3,240 | $71,082.04 | 15,453,629 | |
| BROADWOOD PARTNERS, L.P. | STAA | 10% Owner | Jan 7, 2026 | Buy | $11.00 | 66,467 | $1,462,300.59 | 15,453,629 | |
| BROADWOOD PARTNERS, L.P. | STAA | 10% Owner | Jan 6, 2026 | Buy | $10.85 | 336,946 | $7,284,281.10 | 15,453,629 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Mar 3, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYMar 3, 2026 · 100% conf.
1D
+4.43%
$19.76
Act: +1.59%
5D
+9.38%
$20.69
20D
+5.20%
$19.90
8-K
0000718937STAAR SURGICAL CO00007189372025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 3, 2026
STAAR Surgical Company (Exact Name of Registrant as Specified in Charter)
Delaware
0-11634
95-3797439
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
25510 Commercentre Drive Lake Forest, California
92630
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 626-303-7902 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common
STAA
NASDAQ
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On March 3, 2026, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter and year ended January 2, 2026, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
Item 7.01 Regulation FD Disclosure.
During a conference call and webcast scheduled to be held at 5:30 p.m. Eastern / 2:30 p.m. Pacific on March 3, 2026, the Company’s Interim Co-Chief Executive Officer, President and Chief Operating Officer and the Company's Interim Co-Chief Executive officer and Chief Financial Officer will discuss the Company’s results for the quarter and year ended January 2, 2026. The Company’s shareholder letter for the conference call is furnished as Exhibit 99.2 to this Current Report.
The information furnished herewith pursuant to Items 2.02 and 7.01 of this Current Report, including Exhibits 99.1 and 99.2, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Items 2.02 and 7.01 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.
Description
99.1
Press release of the Company dated March 3, 2026.
99.2
Shareholder letter of the Company dated March 3, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STAAR Surgical Company
March 3, 2026
By:
/s/ DEBORAH ANDREWS
Deborah Andrews
Interim Co-Chief Executive Officer and
Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K BUY Nov 5, 2025 · 100% conf.
Q3 2025 Earnings
8-K BUYNov 5, 2025 · 100% conf.
1D
+4.27%
$26.33
Act: +5.66%
5D
+10.25%
$27.84
Act: +2.38%
20D
+5.19%
$26.56
Act: +5.35%
8-K
0000718937STAAR SURGICAL CO00007189372025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 5, 2025
STAAR Surgical Company (Exact Name of Registrant as Specified in Charter)
Delaware
0-11634
95-3797439
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
25510 Commercentre Drive Lake Forest, California
92630
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 626-303-7902 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common
STAA
NASDAQ
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2025, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended September 26, 2025, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
The information furnished herewith pursuant to Item 2.02 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.
Description
99.1
Press release of the Company dated November 5, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STAAR Surgical Company
November 5, 2025
By:
/s/ Stephen C. Farrell
Stephen C. Farrell
Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K BUY Oct 20, 2025 · 100% conf.
Q3 2025 Earnings
8-K BUYOct 20, 2025 · 100% conf.
1D
+4.27%
$26.33
Act: +5.66%
5D
+10.25%
$27.84
Act: +2.38%
20D
+5.19%
$26.56
Act: +5.35%
8-K
STAAR SURGICAL CO false 0000718937 0000718937 2025-10-20 2025-10-20
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2025
STAAR Surgical Company (Exact name of registrant as specified in its charter)
Delaware
0-11634
95-3797439
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification Number)
25510 Commercentre Drive
Lake Forest, California
92630
(Address of principal executive offices)
(Zip Code) 626-303-7902 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common
STAA
NASDAQ
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On October 20, 2025, STAAR Surgical Company (the “Company”) published a press release reporting its preliminary net sales results for the quarter ended September 26, 2025, a copy of which is filed as Exhibit 99.1 to this report and is incorporated herein by this reference.
Item 9.01 Financial Statements and Exhibits.
Exhibit Number
Exhibit
99.1
Press release of the Company dated October 20, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STAAR Surgical Company
Date: October 20, 2025
By:
/s/ Stephen C. Farrell
Name:
Stephen C. Farrell
Title:
Chief Executive Officer
Compare STAA vs Leading Stocks
See how STAA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "STAA STAAR Surgical Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.